82110-13-2

Basic information

• Product Name: (2S,4S)-2-Methyl-tetrahydro-2H-pyran-4-ol
• Synonyms: (2S,4S)-2-Methyl-tetrahydro-2H-pyran-4-ol
• CAS NO: 82110-13-2
• Molecular Weight: 116.16
• Mol File: 82110-13-2.mol

Chemical Properties

• CAS DataBase Reference: (2S,4S)-2-Methyl-tetrahydro-2H-pyran-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4S)-2-Methyl-tetrahydro-2H-pyran-4-ol(82110-13-2)
• EPA Substance Registry System: (2S,4S)-2-Methyl-tetrahydro-2H-pyran-4-ol(82110-13-2)

Safety Data

• Hazardous Substances Data: 82110-13-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2S,4S)-2-Methyl-tetrahydro-2H-pyran-4-ol is used as a building block in organic synthesis for the preparation of more complex molecules, leveraging its unique structure and chirality.
Used in Pharmaceutical Industry:
(2S,4S)-2-Methyl-tetrahydro-2H-pyran-4-ol is used as an intermediate in the pharmaceutical industry for the development of new drugs, owing to its potential to be incorporated into medicinal compounds.
Used in Fragrance Industry:
(2S,4S)-2-Methyl-tetrahydro-2H-pyran-4-ol is used as a component in the fragrance industry to impart specific olfactory characteristics to perfumes and scented products.
Used in Antimicrobial Applications:
(2S,4S)-2-Methyl-tetrahydro-2H-pyran-4-ol is studied for its potential antimicrobial properties, which could be utilized in the development of new antimicrobial agents.
Used in Anti-Fungal Applications:
(2S,4S)-2-Methyl-tetrahydro-2H-pyran-4-ol is also being investigated for its antifungal properties, indicating its potential use in treating fungal infections.

Upstream product

• 1193-20-0 2-methyltetrahydro-4H-pyran-4-one 
• 33747-08-9 cis-2-methyltetrahydro-2H-pyran-4-ol 
• 627-27-0 homoalylic alcohol 
• 75-07-0 acetaldehyde 
• 123-20-6 vinyl n-butyrate 

Downstream Products

• 1193-20-0 2-methyltetrahydro-4H-pyran-4-one 
• 33747-08-9 (2R,4R)-2-methyltetrahydro-2H-pyran-4-ol 
• 75-07-0 acetaldehyde 
• 1307304-60-4 ((S)-2-(methoxycarbonylamino)-2-((2S,4R)-2-methyltetrahydro-2H-pyran-4-yl)acetic acid) 
• 1306729-73-6 MeI 
• 133813-44-2 (2S,4R)-4-<3-(benzyloxy)-5-fluorophenyl>-4-methoxy-2-methyl-3,4,5,6-tetrahydro-2H-pyran 
• 146565-13-1 (2S,4S)-4-<3-(benzyloxy)-5-fluorophenyl>-4-methoxy-2-methyl-3,4,5,6-tetrahydro-2H-pyran 
• 146565-11-9 (2S,4R)-4-(3-Benzyloxy-5-fluoro-phenyl)-2-methyl-tetrahydro-pyran-4-ol 
• 146565-10-8 (2S,4S)-4-(3-benzyloxy-5-fluorophenyl)-4-hydroxy-2-methyltetrahydropyran 

Relevant articles and documents

CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES

The present invention provides novel cyclic substituted imidazo[4,5- c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof, wherein R1, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors

The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Utilizing on- and off-line monitoring tools to follow a kinetic resolution step during flow synthesis

In situ reaction monitoring tools offer the ability to track the progress of a synthetic reaction in real time to facilitate reaction optimization and provide kinetic/mechanistic insight. Herein, we report the utilization of flow NMR, flow IR, and other off-line spectroscopy tools to monitor the progress of a flow chemistry reaction. The on-line and off-line tools were selected to facilitate the stereoselective kinetic resolution of a key racemic monomer, which lacked a chromophore, making conventional reaction monitoring difficult. Copyright

Enzymes in Organic Synthesis. 25. Heterocyclic Ketones as Substrates of Horse Liver Alcohol Dehydrogenase. Highly Stereoselective Reductions of 2-Substituted Tetrahydropyran-4-ones

Horse liver alcohol dehydrogenase (HLADH) has been found to be an efficient catalyst for the reduction of O-heterocyclic ketones.Preparative-scale HLADH-catalyzed reductions of 2-substituted tetrahydropyran-4-ones are enantioselective, with reduction of e